V 270

Drug Profile

V 270

Alternative Names: HBsAg-1018; HBV vaccine preventative - Dynavax; HBV-ISS preventative vaccine; Hepatitis B Vaccine (Recombinant), Adjuvanted; Hepatitis B vaccine 1018-ISS conjugate - Dynavax; Hepatitis B vaccine preventative - Dynavax; HEPLISAV; HEPLISAV-B; V270

Latest Information Update: 11 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dynavax Technologies
  • Class Hepatitis B vaccines; Oligonucleotides; Synthetic vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 11 Apr 2018 Dynavax Technologies has patent protection for its TLR agonists contained in HEPLISAV-B
  • 08 Jan 2018 Launched for Hepatitis B (Prevention) in USA (IM)
  • 09 Nov 2017 Dynavax plans to launch V 270 for Hepatitis B in USA in the first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top